Neel Talwar, MD
Hematology & Oncology · Upland, CANPI 1477977114
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (43.7%), education and consulting fees — rather than concentrated in one kind of arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 17.3%. Reporting peaked in 2021 at $910 and has fallen 95.8% since, to $39 in 2025. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 27 payments — averaging $107.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$500
- AstraZeneca$419
- Lilly USA, LLC$355
- AVEO Pharmaceuticals, Inc.$325
- Novocure GmbH$250
- Genentech USA, Inc.$238
- plus $805 from 9 others
What the payments were for
- Consulting fees$50017%
- Speaking & faculty fees$2509%
- Food & beverage$1,26244%
- Education$87930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 1 | $500 |
| AstraZeneca(2 entities) | 4 | $419 |
| Lilly USA, LLC | 3 | $355 |
| AVEO Pharmaceuticals, Inc. | 3 | $325 |
| Novocure GmbH | 1 | $250 |
| Genentech USA, Inc. | 2 | $238 |
| Iovance Biotherapeutics, Inc. | 1 | $137 |
| Incyte Corporation | 1 | $135 |
| Karyopharm Therapeutics Inc. | 2 | $130 |
| E.r. Squibb & Sons, L.L.C. | 1 | $108 |
| GSK | 1 | $99 |
| Coherus Oncology, Inc. | 1 | $71 |
| Johnson & Johnson(2 entities) | 3 | $60 |
| Merck | 2 | $53 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,891 in reported general payments places this provider in the 45th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VenclextaVenetoclax | 36 | $559,043 |
| ErleadaApalutamide | 27 | $405,571 |
| XtandiEnzalutamide | 30 | $401,440 |
| CabometyxCabozantinib S-Malate | 16 | $388,529 |
| LenvimaLenvatinib Mesylate | 14 | $314,183 |
| Kisqali Femara Co-PackRibociclib Succinate/Letrozole | 15 | $229,420 |
| KisqaliRibociclib Succinate | 14 | $196,651 |
| AlecensaAlectinib Hcl | 13 | $181,668 |
| TagrissoOsimertinib Mesylate | 11 | $163,467 |
| Abiraterone Acetate | 61 | $152,805 |
| GilotrifAfatinib Dimaleate | 13 | $140,263 |
| Lenalidomide | 11 | $137,802 |
| EliquisApixaban | 89 | $67,337 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 27 | $60,711 |
| BrukinsaZanubrutinib | 12 | $56,791 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada, Xarelto | $60 | $431,18665 claims |
| Genentech USA, Inc.Alecensa | $238 | $181,66813 claims |
| AstraZenecaTagrisso | $419 | $163,46711 claims |
| Lilly USA, LLCOlanzapine | $355 | $18719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Upland
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.